A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine

Category Primary study
JournalEuropean Journal of Cancer
Year 2015
This article has no abstract
Epistemonikos ID: f8fc7093df3b90e463fa5fbe338174984f65ca82
First added on: Feb 07, 2025